UniSA: Clinical and Health Sciences, University of South Australia, Adelaide, Australia; Basil Hetzel Institute for Translational Medical Research, The Queen Elizabeth Hospital, Woodville, Australia; Saudi Arabian Cultural Mission, Ministry of Education, Riyadh, Saudi Arabia; Health and Biomedical Innovation, University of South Australia, Adelaide, Australia.
UniSA: Clinical and Health Sciences, University of South Australia, Adelaide, Australia.
J Pharm Biomed Anal. 2021 Sep 5;203:114171. doi: 10.1016/j.jpba.2021.114171. Epub 2021 May 27.
A range of opioids are commonly prescribed to manage chronic pain, but individual patient responses vary greatly, especially in older populations. One source of that variability are differences in absorption, metabolism and excretion, i.e. pharmacokinetics. Blood, plasma and serum concentrations of opioids allow that variability to be quantified and may be used to optimise opioid dosing. As an aid to that process, there is an unmet need to rapidly quantify several opioids and their metabolites in a single analytical method.
To develop a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for simultaneous quantification of tramadol, oxycodone, fentanyl and their major metabolites in various human matrices.
Sample preparation involved adding three deuterated internal standards followed by protein precipitation with 100 % acetonitrile, evaporation and reconstitution. Separation of analytes via LC was achieved on a reversed phase column via binary gradient elution using 0.005 % formic acid in water and 100 % acetonitrile as mobile phases. Analytes were detected via MS/MS with multiple reaction monitoring (MRM).
The method was accurate with the inter-day and intra-day accuracy of quality control samples (QCs) below 15 %. It was also precise with inter-day and intra-day coefficient of variation below 15 %. The lower limit of quantification (LLOQ) was 0.2 ng/mL for all analytes except tramadol and its metabolites, where the LLOQ was 10 ng/mL. Recovery was greater than 88 % for all analytes, except for O-desmethyltramadol (81 %). Analytes were stable over four freeze-thaw cycles, for 24 h on the bench top and for 24 h post-preparation. The inter- and intra-day variability of concentrations determined in blood and plasma were within 84-124%, whereas the inter- and intra-day variability for blood samples prepared using volumetric absorptive micro-sampling (VAMS) compared to those prepared from whole blood ranged between 83-122%.
A LC-MS/MS method is described that is able to accurately and precisely quantify a number of commonly prescribed opioids and their major metabolites in plasma and whole blood, including whole blood collected using VAMS.
临床上通常会使用多种阿片类药物来治疗慢性疼痛,但不同患者的反应差异很大,尤其是在老年人群中。这种差异的一个来源是吸收、代谢和排泄(即药代动力学)的差异。阿片类药物的血液、血浆和血清浓度可以定量这种变异性,并可用于优化阿片类药物的剂量。作为这一过程的辅助手段,人们迫切需要开发一种能够在单一分析方法中快速定量多种阿片类药物及其代谢物的方法。
建立一种同时定量检测各种人体基质中曲马多、羟考酮、芬太尼及其主要代谢物的液相色谱-串联质谱(LC-MS/MS)方法。
样品制备包括加入三种氘代内标物,然后用 100%乙腈沉淀蛋白,蒸发并复溶。通过反相色谱柱,以 0.005%甲酸水和 100%乙腈为流动相进行二元梯度洗脱,实现分析物的分离。通过多反应监测(MRM)对分析物进行 MS/MS 检测。
该方法日内和日间质控样品(QC)的准确度均低于 15%,精密度也低于 15%。除曲马多及其代谢物的定量下限(LLOQ)为 10ng/mL 外,所有分析物的LLOQ均低于 0.2ng/mL。除 O-去甲基曲马多(81%)外,所有分析物的回收率均大于 88%。分析物在经历四次冻融循环、在实验台上 24 小时以及在制备后 24 小时内均稳定。在血液和血浆中测定的浓度的日内和日间变异性在 84-124%之间,而使用体积吸收微采样(VAMS)采集的血液样本与全血制备的样本相比,其日内和日间变异性在 83-122%之间。
本文描述了一种能够准确、精密地定量检测血浆和全血中多种常用阿片类药物及其主要代谢物的 LC-MS/MS 方法,包括使用 VAMS 采集的全血。